PRKCA and cancer: HDACis have been administered to HIV-infected study participants without serious adverse events (8–10, 35, 59, 60), whereas administration of the PKCa Bryostatin has been associated with toxicities including severe myalgia and nausea in patients with persistent or advanced cancers (61, 62).